Literature DB >> 3316279

Abnormal regulation of renal kallikrein in experimental diabetes. Effects of insulin on prokallikrein synthesis and activation.

A A Jaffa1, D H Miller, G S Bailey, J Chao, H S Margolius, R K Mayfield.   

Abstract

The effects of streptozotocin (STZ) diabetes and insulin on regulation of renal kallikrein were studied in the rat. 1 and 2 wk after STZ injection, diabetic rats had reduced renal levels and urinary excretion of active kallikrein. Tissue and urinary prokallikrein levels were unchanged, but the rate of renal prokallikrein synthesis relative to total protein synthesis was reduced 30-45% in diabetic rats. Treatment of diabetic rats with insulin prevented or reversed the fall in tissue level and excretion rate of active kallikrein and normalized prokallikrein synthesis rate. To further examine insulin's effects, nondiabetic rats were treated with escalating insulin doses to produce hyperinsulinemia. In these rats, renal active kallikrein increased. Although renal prokallikrein was not increased significantly by hyperinsulinemia, its synthesis was increased. As this was accompanied by proportionally increased total protein synthesis, relative kallikrein synthesis rate was not changed. Excretion of active kallikrein was unchanged, but prokallikrein excretion was markedly reduced. Therefore, increased tissue active kallikrein seen with hyperinsulinemia can be explained not only by increased synthesis but also by retention and increased activation of renal prokallikrein. These studies show that STZ diabetes produces an impairment in renal kallikrein synthesis and suggest that this disease state also impairs renal prokallikrein activation. The findings also suggest that insulin modulates renal kallikrein production, activation, and excretion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316279      PMCID: PMC442436          DOI: 10.1172/JCI113254

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  The role of the kidney in the inactivation of injected [125I]kallikrein.

Authors:  I H Mills; C L Paterson; P E Ward
Journal:  J Physiol       Date:  1975-10       Impact factor: 5.182

2.  The regulation of phosphoenolpyruvate carboxykinase (GTP) synthesis in rat kidney cortex. The role of acid-base balance and glucocorticoids.

Authors:  P B Iynedjian; F J Ballard; R W Hanson
Journal:  J Biol Chem       Date:  1975-07-25       Impact factor: 5.157

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake.

Authors:  S B Levy; J J Lilley; R P Frigon; R A Stone
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

5.  Effect of experimental hyperinsulinemia on insulin binding and glucose transport in isolated rat adipocytes.

Authors:  M Kobayashi; J M Olefsky
Journal:  Am J Physiol       Date:  1978-07

6.  Site of kininogenase secretion in the dog nephron.

Authors:  A G Scicli; O A Carretero; A Hampton; P Cortes; N B Oza
Journal:  Am J Physiol       Date:  1976-02

7.  Protein synthesis during compensatory renal hypertrophy.

Authors:  F L Coe; P R Korty
Journal:  Am J Physiol       Date:  1967-12

8.  The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man.

Authors:  R A DeFronzo; C R Cooke; R Andres; G R Faloona; P J Davis
Journal:  J Clin Invest       Date:  1975-04       Impact factor: 14.808

9.  A direct radioimmunoassay of rat urinary kallikrein and comparison with other measures of urinary kallikrein activity.

Authors:  K Shimamoto; H S Margolius; J Chao; A R Crosswell
Journal:  J Lab Clin Med       Date:  1979-07

10.  Renal hypertrophy in streptozotocin-diabetic rats.

Authors:  K Seyer-Hansen
Journal:  Clin Sci Mol Med       Date:  1976-12
View more
  9 in total

Review 1.  Tissue kallikreins structure, regulation, and participation in mammalian physiology and disease.

Authors:  H S Margolius
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

2.  Increased tissue kallikrein levels in type 2 diabetes.

Authors:  D J Campbell; A Kladis; Y Zhang; A J Jenkins; D L Prior; M Yii; J F Kenny; M J Black; D J Kelly
Journal:  Diabetologia       Date:  2010-01-10       Impact factor: 10.122

Review 3.  The kinin system in hypertensive pathophysiology.

Authors:  Jagdish N Sharma
Journal:  Inflammopharmacology       Date:  2012-04-17       Impact factor: 4.473

4.  Evidence for renal kinins as mediators of amino acid-induced hyperperfusion and hyperfiltration in the rat.

Authors:  A A Jaffa; C P Vio; R H Silva; R J Vavrek; J M Stewart; P F Rust; R K Mayfield
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

5.  Altered renal kallikrein and renin gene expression in nephrotic rats and modulation by converting enzyme inhibition.

Authors:  F N Hutchison; S K Webster; A A Jaffa
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

6.  Urinary kallikrein excretion in type 1 (insulin-dependent) diabetes mellitus.

Authors:  A Manto; P Cotroneo; G Porcelli; G D'Errico; G Marra; P Magnani; P Tilli; A V Greco; G Ghirlanda
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

7.  Renal excretion of kallikrein and eicosanoids in patients with type 1 (insulin-dependent) diabetes mellitus. Relationship to glomerular and tubular function.

Authors:  J N Harvey; A W Edmundson; A A Jaffa; L L Martin; R K Mayfield
Journal:  Diabetologia       Date:  1992-09       Impact factor: 10.122

Review 8.  Pathophysiology of the diabetic kidney.

Authors:  Volker Vallon; Radko Komers
Journal:  Compr Physiol       Date:  2011-07       Impact factor: 9.090

9.  Insulin receptors along the rat nephron: [125I] insulin binding in microdissected glomeruli and tubules.

Authors:  D Butlen; S Vadrot; S Roseau; F Morel
Journal:  Pflugers Arch       Date:  1988-10       Impact factor: 3.657

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.